Can a Wearable Track Perimenopause? What Oura, Apple and Sensors Measure, and What Hasn't Been Validated

Short answer: wearables can track signals that change through the menopause transition, and in 2026 Oura and Apple made life stage a feature, but no major brand has published a clinical trial validating its data for perimenopause.

That gap is the most important thing to understand about a fast-growing part of women’s health. The need is large and long. Frequent hot flashes and night sweats last a median of 7.4 years [1], menopause symptoms cost US employers an estimated $1.8 billion a year in lost work time [2], and the sensors on rings and watches measure exactly the physiology that shifts. What is missing is evidence that consumer devices can identify the transition or count symptoms reliably. This post covers what shipped, what the sensors can and cannot tell, and what employers, health plans and apps should build.

How big is the need?

Symptoms last years. In the Study of Women’s Health Across the Nation (SWAN), which followed 3,302 women at seven US sites, the median total duration of frequent vasomotor symptoms was 7.4 years, with a median of 4.5 years after the final period. Women whose symptoms began while still premenopausal or early perimenopausal had the longest duration, a median of more than 11.8 years [1].

Symptoms affect work. In a Mayo Clinic survey of 4,440 employed women aged 45 to 60, 13.4% reported at least one adverse work outcome due to menopause symptoms and 10.8% had missed work in the previous year, a median of three days. Women in the highest quartile of symptom severity were 15.6 times more likely to report an adverse work outcome than those in the lowest. The authors estimated about $1.8 billion a year in lost US work time [2].

Treatment options have widened. Alongside hormone therapy, the FDA approved fezolinetant, a non-hormonal treatment for moderate to severe vasomotor symptoms, in 2023, and elinzanetant has since been approved after the OASIS trial program showed reductions in symptom frequency and improvements in sleep disturbance [3]. More treatments make better measurement more valuable: a symptom that can be treated is worth tracking.

That combination is why menopause has become a priority for employer wellness programs and for women’s health products.

How is perimenopause defined?

Clinically, mainly by menstrual cycle changes, not by a sensor reading. The STRAW+10 staging system, the reference framework for reproductive aging, defines the early menopausal transition by increasing variability in cycle length and the late transition by long gaps between periods, and recommends applying those criteria regardless of age, ethnicity, body size or lifestyle [4]. Hormone tests are supportive rather than definitive, because levels fluctuate widely during the transition.

That matters for wearables. The most defensible signal a phone or wearable has is the cycle record, whether logged by the user or estimated from temperature. Apple’s perimenopause notification is built on exactly that: logged cycle patterns in users aged 40 and over [5].

What did Oura and Apple ship in 2026?

Oura Menopause Insights, launched on 6 May 2026 for Gen 3 and Gen 4 rings, is built around Oura’s Menopause Impact Scale, a questionnaire covering 22 symptoms. It produces a dashboard of overall impact, contributing domains and how each symptom affects daily life, tracked over time and linked to the ring’s sleep, temperature and heart data. Results can be shared with clinicians, and Oura has care partnerships with Maven, Progyny and Twentyeight Health [6][7].

Apple, with iOS 27, lets users log perimenopause or menopause and their symptoms, notifies users aged 40 and over when logged cycle patterns suggest perimenopause, and prompts users who log bleeding after menopause to speak to a doctor [5]. It also added two HealthKit types that other apps can read and write: menopausal state (menopause, perimenopause or neither) and bleeding after menopause, which is clinically distinct from menstrual flow [8][9]. The rest of the September changes are in Apple’s September health announcements.

Both are built on symptoms and self-reported state, linked to biometrics, rather than on detecting the transition from sensors alone. That is the honest design given the evidence.

What can the sensors measure, and what has been validated?

Rings and watches measure signals that plausibly track the transition:

• Skin temperature, overnight, relative to a personal baseline.
• Sleep, including wake-ups and fragmentation, which night sweats disrupt.
• Resting heart rate and heart rate variability, which shift with sleep disruption and hormonal change.
• Cycle length, where temperature-based cycle estimates or logged periods exist.

The evidence gap is specific. An August 2026 review of the category found that Garmin, Oura, WHOOP, Polar, Fitbit and Withings all supply heart rate, HRV, skin temperature and sleep data to third-party symptom apps, but that none of those brands had a published clinical trial validating its data for perimenopause. The peer-reviewed evidence came instead from smaller purpose-built products and app-based programs [10].

Hot flashes are the clearest example. Research studies have traditionally measured them with skin conductance on the chest. Consumer rings and watches measure skin temperature at the finger or wrist, which can reflect a hot flash but has not been validated as a hot flash counter. Purpose-built devices are appearing to fill the gap: Peri, an adhesive patch worn on the torso that tracks temperature, heart rate, stress signals and movement for hot flashes and night sweats, launched at CES 2026 at $449 [10][11].

Why life stage matters for every health score

Even products that never mention menopause are affected by it.

Most sleep, readiness and recovery scores compare a user with their own recent baseline. When night sweats fragment sleep and skin temperature rises, a baseline model sees poor recovery and, in some cases, a temperature deviation that looks like illness. For a woman in the transition, that is a persistent and misleading signal. The same issue runs through how readiness scores are calculated and what a good sleep score is.

Apple has now made life stage a structured field that apps can read [8]. A product that knows a user is perimenopausal can:

• Explain, not alarm. Attribute temperature and sleep changes to the transition when the user has recorded it, rather than to illness or overtraining.
• Adjust expectations. Avoid repeatedly penalizing sleep that is disrupted for a known, temporary physiological reason.
• Track what matters to the user. Symptom frequency, sleep continuity and the effect of treatment over months.

What should employers, health plans and apps build?

• Start with symptoms the user reports. Validated questionnaires and simple logging are where the evidence is. Biometrics add context to them; they do not replace them.
• Read life stage where it exists. On iPhone, request the menopausal state type in HealthKit and adapt interpretation [8]. On Android, Health Connect has cycle records but no menopause type, so ask the user [12].
• Measure outcomes over months. With symptoms lasting a median of 7.4 years [1], the useful view is trends in sleep continuity, symptom frequency and response to treatment, not daily scores.
• Connect to care. The value for an employer or plan is access to treatment, including newer non-hormonal options [3], and clinician-ready summaries, which is what Oura’s clinician sharing is aiming at [6].
• Stay on the wellness side. Avoid diagnostic language about perimenopause or hot flash counts unless a device has been validated for it; see whether your health app is a medical device.

The short version

Menopause became a wearable feature in 2026: Oura’s Menopause Insights built on a 22-symptom scale [6], and Apple’s iOS 27 logging, perimenopause notification and new HealthKit types [5][8]. Rings and watches measure temperature, sleep, heart rate and cycles that change through the transition, but no major brand has published a trial validating that data for perimenopause [10]. Symptoms last a median of 7.4 years [1] and cost US employers about $1.8 billion a year in lost work time [2]. Build around what users report, use biometrics as context, read life stage where the platform provides it, and keep claims inside what the sensors have been shown to do.